{"id":2817,"date":"2026-09-02T08:00:00","date_gmt":"2026-09-02T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2817"},"modified":"2026-09-01T22:18:37","modified_gmt":"2026-09-02T02:18:37","slug":"upstream-defines-verekitug-phase-iii-programs-after-fda-meetings","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2817","title":{"rendered":"Upstream Defines Verekitug Phase III Programs After FDA Meetings"},"content":{"rendered":"

Company:<\/strong> Upstream Bio · Drug:<\/strong> Verekitug · Indications:<\/strong> Severe Asthma, Chronic Rhinosinusitis with Nasal Polyps · Trial Stage:<\/strong> Phase III (Planned Q1 2027) · Date:<\/strong> September 1, 2026<\/p>\n

\"Upstream<\/p>\n

Summary<\/h4>\n

Following end-of-Phase II meetings with FDA, Upstream Bio disclosed one placebo-controlled pivotal trial each in severe asthma and chronic rhinosinusitis with nasal polyps. Both will test verekitug 400 mg subcutaneously every 12 weeks in broad populations without biomarker restriction, enrolling about 1,500 patients total. Trial initiation remains planned for the first quarter of 2027. The design clarifies a registrational path and quarterly regimen, but FDA agreement on development plans is not an efficacy endorsement or approval commitment.<\/p>\n

What Happened<\/h4>\n

The severe-asthma study will use annualized exacerbation rate over 48 weeks as the primary endpoint. The CRSwNP study will use co-primary changes in nasal-polyp score and nasal-congestion score at Week 48. Upstream selected a higher quarterly regimen than the 100 mg every-12-week dose used in Phase II and abandoned the every-24-week interval that produced a smaller asthma effect. Phase II VALIANT reported 56% lower annualized exacerbation rate with 100 mg every 12 weeks and 39% lower with 400 mg every 24 weeks versus placebo. VIBRANT reported a 1.8-point placebo-adjusted nasal-polyp-score improvement at 24 weeks with every-12-week dosing. More than 500 participants have received verekitug across development programs, according to the company.<\/p>\n

Deep Analysis<\/h4>\n

One pivotal trial per indication, standard clinical endpoints and broad enrollment can create an efficient path to two filings, and quarterly dosing could differentiate verekitug from more frequent biologics if efficacy and safety hold. A single-study strategy, however, concentrates operational and statistical risk, and regulators retain discretion over adequacy of evidence at filing. The 400 mg every-12-week regimen is designed to sustain receptor coverage while preserving a convenient interval, supported by exposure-response analyses and prior safety experience, but this exact dose schedule was not the randomized Phase II asthma regimen that generated the 56% effect, so Phase III must bridge dose, interval and broad biomarker populations prospectively.<\/p>\n

Company and Product Background<\/h4>\n

Upstream Bio is a clinical-stage immunology company focused on severe inflammatory respiratory disease. Verekitug is a fully human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin receptor and blocks signaling initiated by TSLP; targeting the receptor rather than the cytokine is intended to provide potent pathway inhibition and extended dosing. TSLP is an epithelial alarm cytokine upstream of type 2 and other inflammatory cascades. Severe asthma involves recurrent exacerbations, variable airflow limitation and heterogeneous biomarkers; CRSwNP features chronic sinonasal inflammation, polyp growth and obstruction. A broad-label strategy must demonstrate benefit across biomarker-defined phenotypes while maintaining infection, hypersensitivity and immunogenicity safety acceptable for chronic preventive use.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Pivotal Design<\/td>\nOne placebo-controlled Phase III trial each in severe asthma and CRSwNP; ~1,500 patients total<\/td>\n<\/tr>\n
Regimen<\/td>\n400 mg SC every 12 weeks, broad populations, no biomarker restriction<\/td>\n<\/tr>\n
Phase II Support<\/td>\nVALIANT: 56% lower AER (100mg Q12W); VIBRANT: 1.8-pt placebo-adjusted NPS improvement<\/td>\n<\/tr>\n
Timeline<\/td>\nTrial initiation planned Q1 2027<\/td>\n<\/tr>\n
Signal Type<\/td>\nRegulatory-path clarification following FDA end-of-Phase II meetings<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A clear single-pivotal-trial path in two sizable respiratory indications, combined with a convenient quarterly regimen and over 500 patients of prior verekitug exposure, could support an efficient route to two filings for a differentiated TSLP-receptor-targeted biologic.<\/p>\n

Bear case:<\/strong> The single-study strategy concentrates statistical and operational risk, and the selected 400 mg every-12-week regimen was not the exact schedule that generated the strongest Phase II effect, meaning Phase III must prospectively validate an optimized but untested dose and interval.<\/p>\n

InSilens Take<\/h4>\n

The update materially improves visibility into verekitug’s pivotal strategy. Quarterly administration and two broad indications could support a differentiated respiratory franchise, but the chosen regimen is still a prospective optimization rather than a validated commercial profile. The correct positive reading is regulatory-path clarification, not FDA validation of efficacy, safety or best-in-class positioning.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Following end-of-Phase II meetings with FDA, Upstream Bio disclosed one placebo-controlled pivotal trial each in severe asthma and chronic rhinosinusitis with nasal polyps. Both will test verekitug 400 mg subcutaneously every 12 weeks in…<\/p>\n","protected":false},"author":1,"featured_media":2820,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[506,505,503,504],"class_list":["post-2817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-chronic-rhinosinusitis","tag-severe-asthma","tag-upstream-bio","tag-verekitug"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2817"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2817\/revisions"}],"predecessor-version":[{"id":2843,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2817\/revisions\/2843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2820"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}